The new 12,000-sq-ft multiuse facility -- Building 3 -- will provide high-throughput screening, biologics and drug product manufacturing, and analytical support, according to Alchem. Scheduled to be completed by the end of 2020, the building will enable continued and expanded support for products in clinical studies, the company said. Alchem indicated that it will also initiate ISO 9001 certification to support current late-stage clinical trial and commercial manufacturing operations.

The firm is currently supporting seven different five-year contracts with the U.S. National Institutes of Health and the Department of Defense for screening and drug product manufacturing. In addition, Alchem said it has manufactured products in 20 active clinical programs as of the beginning of 2000.